This is the authors' abstract. We don't add key points for this paper.
Background &Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common leading cause of chronic liver damage worldwide, paralleling the prevalence of obesity. We previously reported that the rs17618244 variant in the β-Klotho ( KLB ) gene, encoding the hepatic obligate co-receptor of fibroblast growth factor receptor 4 (FGFR4), reduced KLB hepatic/plasma levels, leading to severe MASLD in both children and adults. This study aimed to evaluate the impact of another variant in the KLB gene, the intronic rs12152703 G>T, on histological liver damage in MASLD patients. Methods The rs12152703 mutation was evaluated in 1311 biopsy-proven MASLD patients, of whom 261 were children and correlated with the disease spectrum. Moreover, we investigated the association of this variant with the expression of hepatic/soluble KLB. Finally, we assessed in an i n vitro model whether KLB overexpression in HepG2 cells impacts lipid homeostasis and inflammation. Results At multivariate analysis, the KLB rs12152703 mutation was associated with reduced transaminases and protection against steatosis, inflammation, and steatohepatitis in the overall cohort (p<0.05). Hepatic/circulating concentrations of KLB were increased in both adult and paediatric MASLD patients carrying the variant (p<0.05). In the in vitro model, KLB overexpression decreased intracellular lipid accumulation in HepG2 cells loaded with free fatty acids by affecting the expression of genes involved in lipid metabolism. Furthermore, KLB induction counteracted lipopolysaccharide (LPS)-induced effects on inflammatory genes and NF-κB (p65) phosphorylation/activation. Conclusions The KLB rs12152703 variant protects against lobular inflammation, thereby enhancing serum and hepatic KLB levels, differently from the rs17618244 at-risk variation. Moreover, KLB overexpression ameliorated steatosis and pro-inflammatory status in fatty-loaded hepatocytes. Thus, KLB may constitute a novel druggable target for the management of severe MASLD. Impact and Implications The study highlights the beneficial effect of a genetic variant in the Klotho-beta ( KLB) gene in mitigating hepatic inflammation and disease severity in both adults and children with metabolic dysfunction-associated steatotic liver disease (MASLD). The mechanism behind these favorable associations appears to be the upregulation of circulating and hepatic KLB protein levels. Accordingly, KLB overexpression ameliorates fat overload in hepatocytes by affecting the expression of genes involved in lipid metabolism. These findings corroborate the idea to outline FGF19/KLB axis as a therapeutic target of severe MASLD.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Meroni et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: